Literature DB >> 2839218

Reduction or loss of HLA-A,B,C antigens in colorectal carcinoma appears not to influence survival.

B Stein1, F Momburg, V Schwarz, P Schlag, G Moldenhauer, P Möller.   

Abstract

Primary colorectal carcinomas of an unselected group of 159 patients 126 of whom could be curatively resected were examined for the expression of MHC class I antigens with monoclonal antibody W6/32 directed against a non-polymorphic determinant of HLA-A,B,C heavy chain. One hundred and nine (68.6%) were found to express HLA-A,B,C antigens in normal quantities, 33 (20.8%) showed a substantial reduction in expression, while 17 (10%) lacked these antigens either completely or incompletely. The loss of HLA-A,B,C was inversely correlated with the degree of differentiation. The tendency of mucinous carcinomas to lack class I antigens was statistically not significant. Tumours with distant metastatic spread at the time of operation tended to be normal with respect to HLA-A,B,C expression. Within the curatively resected group, poor differentiation and mucus production were risk factors for survival as could be shown by life table analysis after a maximum follow-up of 39 months. In contrast, the mode of HLA-A,B,C expression of the primary tumour did not influence survival within this time of observation. We conclude that in spite of increasing experimental data suggesting the contrary, the presence or absence of MHC class I antigens does not seem to profoundly modify tumour biology, at least in human colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839218      PMCID: PMC2246570          DOI: 10.1038/bjc.1988.83

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  The distribution of HLA on human lymphoid, bone marrow and peripheral blood cells.

Authors:  G Brown; P Biberfeld; B Christensson; D Y Mason
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

2.  Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity.

Authors:  R Bernards; P I Schrier; A Houweling; J L Bos; A J van der Eb; M Zijlstra; C J Melief
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

3.  Anomolous expression of HLA-DR antigens on human colorectal cancer cells.

Authors:  A S Daar; S V Fuggle; A Ting; J W Fabre
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

4.  Resistance to cell-mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukemia.

Authors:  W Schmidt; H Festenstein
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

5.  Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies.

Authors:  B Malissen; N Rebai; A Liabeuf; C Mawas
Journal:  Eur J Immunol       Date:  1982-09       Impact factor: 5.532

6.  Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2Kk.

Authors:  L R Gooding
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

7.  Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; A K Bhan
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

8.  Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

Authors:  K A Fleming; A McMichael; J A Morton; J Woods; J O McGee
Journal:  J Clin Pathol       Date:  1981-07       Impact factor: 3.411

9.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

10.  Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease.

Authors:  H L Whitwell; H P Hughes; M Moore; A Ahmed
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

View more
  8 in total

1.  Sporadic loss of leucocyte-function-associated antigen-3 (LFA-3) in colorectal carcinomas.

Authors:  K Koretz; P Schlag; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 2.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

3.  Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

Authors:  M E Smith; S G Marsh; J G Bodmer; K Gelsthorpe; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  HLA antigens are candidate markers for prediction of lymph node metastasis in gastric cancer.

Authors:  K Ogoshi; T Tajima; T Mitomi; K Tsuji
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

5.  Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas.

Authors:  H O Wintzer; M Benzing; S von Kleist
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

6.  Prognostic significance of major histocompatibility complex class II antigens (HLA-DR) in normal colonic mucosa, tubulovillous adenoma, and invasive colonic carcinoma.

Authors:  Demetrio Tamiolakis; Sylvia Nicolaidou; Sophia Bolioti; Anna Tzilivaki
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

7.  Selective loss of beta 2-microglobulin mRNA in human colon carcinoma.

Authors:  F Momburg; S Koch
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

8.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.

Authors:  P Korkolopoulou; L Kaklamanis; F Pezzella; A L Harris; K C Gatter
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.